Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.



11/02/2021 - Bioxodes appoints Dr Hans Warrinnier as Chief Medical Officer.
Read the full Press Release here.

04/29/2021 - Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI, a drug candidate for the prevention of thrombosis.

Read the full Press Release here.